Head-To-Head Review: Parnell Pharmaceuticals (OTCMKTS:PARNF) versus Personalis (NASDAQ:PSNL)

Parnell Pharmaceuticals (OTCMKTS:PARNF) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Parnell Pharmaceuticals and Personalis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parnell Pharmaceuticals	0	0	0	0	0.00
Personalis	1	0	5	0	2.67

Personalis has a consensus target price of $7.42, suggesting a potential downside of 2.03%. Given Personalis’ stronger consensus rating and higher possible upside, analysts clearly believe Personalis is more favorable than Parnell Pharmaceuticals.

Profitability

This table compares Parnell Pharmaceuticals and Personalis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parnell Pharmaceuticals	N/A	N/A	N/A
Personalis	-113.70%	-47.57%	-35.05%

Insider & Institutional Ownership

61.9% of Personalis shares are owned by institutional investors. 3.8% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Parnell Pharmaceuticals has a beta of 26.39, indicating that its stock price is 2,539% more volatile than the S&P 500. Comparatively, Personalis has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500.

Earnings and Valuation

This table compares Parnell Pharmaceuticals and Personalis”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parnell Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Personalis	$84.61 million	7.93	-$81.28 million	($1.28)	-5.91

Parnell Pharmaceuticals has higher earnings, but lower revenue than Personalis.

Summary

Personalis beats Parnell Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

About Parnell Pharmaceuticals

Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal – U.S., Production Animal – Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.

About Personalis

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.